Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.54 |
| ▸ | IARS1 | P41252 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 7/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13643394 | 0.91 | IARS1 (0.46) | MIFIARS1MARS1PTPN1MEN1 | |
| SCHEMBL12607618 | 0.89 | MIF (0.47) | MIFIARS1MAOBPTPN1 | |
| SCHEMBL12607573 | 0.89 | MIF (0.44) | MIFMAOBPTPN1MAPTMAPK1 | |
| SCHEMBL13643396 | 0.88 | PTPN1 (0.40) | MIFPTPN1MAPTMAPK1 | |
| SCHEMBL13643400 | 0.83 | PTPN1 (0.40) | MIFMAOBPTPN1 | |
| SCHEMBL1015152 | 0.83 | MIF (0.57) | MIFIARS1MARS1MAOAMAOB | |
| SCHEMBL13643398 | 0.83 | PTPN1 (0.43) | MIFIARS1MARS1MAOBPTPN1 | |
| SCHEMBL13643389 | 0.78 | PPARG (0.43) | MAOBPTPN1 | |
| SCHEMBL13660015 | 0.76 | MIF (0.51) | MIFPTPN1MAPT | |
| SCHEMBL5689279 | 0.74 | TUBB4A (0.49) | MIFIARS1MARS1PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372831-B2 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-02-12 | — | — | US | disclosed |
| US-20110118237-A1 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118237-A1 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | GABRA5, GABRA1, CYP3A7 | MIF 3861/4885IARS1 638/4885MARS1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.